Dezapelisib Uses, Dosage, Side Effects and more
Dezapelisib is under investigation in clinical trial NCT02456675 (INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/refractory Hodgkin Lymphoma).
| Trade Name | Dezapelisib |
| Generic | Dezapelisib |
| Dezapelisib Other Names | Dezapelisib |
| Type | |
| Formula | C20H16FN7OS |
| Weight | Average: 421.45 Monoisotopic: 421.1121075 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | January 7, 2025 at 1:49 am |
